NHS to use world-first ‘subscription-style’ model to tackle AMR

NHS to use world-first ‘subscription-style’ model to tackle AMR

Contracts are set to be offered to pharmaceutical companies, paying them at the beginning of their work, in order to incentivise work in bringing new antibiotics to market which could counteract antimicrobial resistance (AMR).

As part of the deals, of which the NHS reportedly has two contracts ready to offer, the healthcare service would secure access to the innovative treatments, with NHS patients potentially able to benefit from them as early as 2022.

It will represent the world’s first ‘subscription-style’ payment model for antibiotics and is likely to target development of new antibiotics to treat some of the deadliest diseases. Of particular interest are antibiotics which can provide alternative treatments for serious infections, such as bloodstream infections, sepsis and hospital-acquired pneumonia.

Often, the high costs and low returns associated with antibiotic research and development make it a commercially unattractive enterprise for the pharmaceutical industry, prompting the unique ‘subscription-style’ payment model approach the UK government is taking in this instance.

Health Secretary Matt Hancock said: “The incredible discovery of antibiotics nearly 100 years ago transformed the health of our nation and our ability to combat infections. Diseases that were once a death sentence are now treated in just one small step.

“But resistance to antibiotics is increasing and it’s imperative we take urgent action on a national and global scale to protect future generations.

“This new way of buying antibiotics for patients in the NHS breaks down restrictive barriers to offer companies a vital springboard to foster innovation and develop potentially life-saving new products.”

The contracts represent the world’s first ‘subscription-style’ payment model for antibiotics and is likely to target development of new antibiotics to treat some of the deadliest diseases

The contracts represent the world’s first ‘subscription-style’ payment model for antibiotics and is likely to target development of new antibiotics to treat some of the deadliest diseases

Professor Dame Sally Davies, UK Special Envoy on Antimicrobial Resistance, added: “Antibiotics underpin modern medicine and are integral for global health security. Governments and industry must work together to produce new antibiotics and ensure that we can continue to treat common diseases.

“The UK is leading the way by encouraging companies to produce new antibiotics to stay one step ahead of life-threatening diseases.”

The payment model, which was launched back in July 2019, will pay pharmaceutical companies upfront for access to their antibiotic product, based on a product’s value to the NHS, rather than how much is used.

This aims to incentivise companies to invest in researching and developing new antibiotics, helping secure much-needed alternative treatment options for NHS patients.

Two drugs which have proven to be both safe and effective during trials will then be selected to undergo health technology assessment (HTA) by NICE throughout 2021 using adapted methods for antimicrobials. The HTA will be used to decide the level of the subscription payment.

From this week, suppliers can register their interest for the scheme on NHS England’s eTendering Service.

NHE July/August 21

NHE July/August 21

Prioritising staff wellbeing

NHE’s July/August 2021 edition focuses on some of the key, defining aspects of a successful, supported health service: Mental Health & Workforce. Elsewhere, we take on the incredibly topical Infection Prevention and address the role which Pharma will play in both our NHS and wider health environment.

Videos...

View all videos
National Health Executive Presents

National Health Executive Presents

NHE365 Virtual Festival: Net-Zero NHS

As was outlined by Sir Simon Stevens when the NHS announced their green plans back in 2020, 5,700 lives could be saved each year by improved air quality. Even more could see their overall health improve and be in a position to self-manage their conditions, rather than requiring NHS treatment. Covid-19 has already left the NHS with a sizeable treatment backlog, so anything which can be done to improve patient health and reduce demand is beneficial for all.

Working together, we can help the NHS realise its green ambitions as per the Net-Zero National Health Service report and its ambitious 2040 target. Join us on August 25, 2021 for our Net-Zero NHS event, where we will be joined by health sector leaders and innovators for a day of sharing best practice and networking.

Finger on the Pulse

Ep 14. Health messaging is a science, Professor Craig Jackson

On Episode 14 of NHE's Finger on the Pulse podcast, we're joined by Professor Craig Jackson, Professor of Occupational Health Psychology
Birmingham City University to discuss the coronavirus pandemic, the health messaging around it and how those in power have missed a trick by overlooking the key role of psychology in informing the public of restrictions, measures and the ever-changing situation

More articles...

View all